The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $24 from $30 and keeps a Market Perform rating on the ...

Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...

Discover Vertex’s Q3 2025 earnings: strong cloud growth, new CEO, $150M share buyback, and AI investments amid guidance cuts.

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...

Anna Coren, CBS News foreign correspondent based in Hong Kong, is an Emmy Award-winning international correspondent who covers the Asia-Pacific region. East China Sea — Over the deep blue waters of ...

Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

The Israeli navy intercepted another flotilla — the second in recent days — headed to Gaza in an attempt to pass through Israel's Naval border in an display of activism. The Freedom Flotilla Coalition ...